Pharmasset Reports First Fiscal Quarter 2008 Financi...(ated potent anti-HCV activity. Antici...),Health

Anticipated Highlights

-- Oral presentation of the final safety and efficacy data from two

cohorts from the third part of a Phase 1 study of R7128 following 4

weeks of combination therapy with Pegasys plus Copegus at the 43rd

Annual Meeting of the European Association for the Study of the Liver

(EASL) being held from April 23-27, 2008 in Milan, Italy.

-- Complete HBV patient enrollment for clevudine Phase 3 registration

clinical trials in the second calendar half of 2008.

-- Initiate HCV patient screening for a 12-week Phase 2b combination

study of R7128 with Pegasys plus Copegus in the fourth calendar

quarter of 2008, assuming the successful completion of the on-going

R7128 Phase 1 study, transfer of our IND for R7128 to Roche, consent

from the FDA and timely completion of all required Phase 2b study

preparation activities.

-- Conducting preclinical studies of a proprietary anti-HCV nucleoside

analog to support first-in-human clinical trials, once a lead compound

has been nominated from the series.

About Pharmasset

Pharmasset is a clinical-stage pharmaceutical company committed to discovering, developing and commercializing novel drugs to treat viral infections. Pharmasset's primary focus is on the development of oral therapeutics for the treatment of hepatitis B virus (HBV), hepatitis C virus (HCV) and human immunodeficiency virus (HIV).

Pharmasset is currently developing three product candidates. Clevudine, for the treatment of chronic HBV infection, is enrolling Phase 3 clinical trials for registration in North, Central and South America and Europe. Clevudine is already approved for HBV in South Korea and marketed by Bukwang Pharmaceuticals in South Korea under the brand name Levovir. R7128, an oral treatment for chronic HCV infection, is in a 4-week Phase 1
'/>"/>